Krystal Biotech's VYJUVEK sees strong growth with $1B+ 2025 sales forecast. Check out why I rate KRYS as a Strong Buy and my ...

South Side-based biotechnology firm Krystal Biotech Inc.'s stock is up 20% following its earnings call this morning.

Krystal Biotech KRYS reported fourth-quarter earnings per share of $1.52, which beat the Zacks Consensus Estimate of $1.29 as ...

Q4 2024 Management View CEO Krish Krishnan highlighted 2024 as a strong year, driven by the continued success of the VYJUVEK launch in the U.S., which is tracking as a top-tier rare disease launch. He ...

Fourth quarter revenues increased 116% to $91.1 million versus fourth quarter of 2023Full year revenues increased 473% to $290.5 million versus ...

Citi analyst Yigal Nochomovitz raised the firm’s price target on Krystal Biotech (KRYS) to $215 from $206 and keeps a Neutral rating on the ...

Krystal Biotech Inc (KRYS) reports robust financial performance with significant revenue growth and strategic advancements in ...

Krish S. Krishnan, the CEO, emphasized the focus for 2025 on the global launch of VYJUVEK and reaching key milestones in their genetic medicine initiatives. The company highlighted continued high ...

Krishnan, Chairman and CEO of Krystal Biotech. “Building on this foundation, our focus in 2025 will be on executing the global launch of VYJUVEK and progressing our rare disease and oncology ...